Pharma & Biotech Mergers & Acquisitions News

2024 pharma and biotech M&A deals exceed 2023 in numbers but not value

2024 pharma and biotech M&A deals exceed 2023 in numbers but not value

Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025

Regeneron eyes novel drug delivery with Oxular buy

3 January 2025

HOOKIPA Pharma in early talks to acquire Poolbeg

2 January 2025

Inmagene takes back-door route to Nasdaq listing

27 December 2024

Shionogi to acquire full ownership of joint ventures with Ping An

23 December 2024

Today's issue

UCB collaborates with Ailux to accelerate biologics discovery

UCB collaborates with Ailux to accelerate biologics discovery

9 January 2025

Grifols files fibrinogen BLA

9 January 2025

Active deal-making day for Boehringer, with two ADC collabs

9 January 2025

DBV up 10% as confidence grows in peanut patch

9 January 2025

Bayer Phase III success with elinzanetant

9 January 2025

MitoRx strengthens team as obesity program advances

9 January 2025

Subcutaneous Sarclisa scores Phase III win

9 January 2025

Refine Search

Latest Mergers & Acquisitions News & Features

Opko buys assets from Schering-Plough; acquires Chilean drugmaker

Miami, USA-based Opko Health has agreed to acquire from drug major Schering-Plough assets relating to a neurokinin-1 receptor antagonist program, marking Opko's latest step away from the RNAi drugs space. The companies did not disclose the terms of the agreement. 16 October 2009

Previous page 75 76 77 7879

Immedica acquires Marinus in $151 million deal

Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025

2024 pharma and biotech M&A deals exceed 2023 in numbers but not value

Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025

Regeneron eyes novel drug delivery with Oxular buy

Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025

Novo Nordisk invests in new production facility in Odense

Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024

Biopharma sector ready for surge in M&A activity in 2025

The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024

Bausch + Lomb responds to rumors of a potential sale

Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024

Tenpoint and Visus unite ahead of presbyopia drop filing

UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024

EC approves Novo Holdings' buy of Catalent

The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024

GE drawn to radiopharma boom with strategic buy

GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024

Turbulent times at Evotec as COO steps down

Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024

Adragos Pharma acquires Baccinex

Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024

Grifols says takeover talks with Brookfield terminated

The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024

Novartis upgrades mid-term guidance; buys Kate Thera

Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024

Decoding big pharmas’ next move in a more complex China

Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024

Syncona launches new portfolio company Slingshot Therapeutics

Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024

EU sets date for decision on proposed $16.5 billion Catalent buy

European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024

The Pharma Letter M&A roundup - October 2024

Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024

The week in pharma: action, reaction and insight – week to November 1

US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024

Telix spins off radiopharma unit to form Rhine Pharma

Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024

Sanofi to sell CD&R 50% controlling stake in Opella

French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024

12 3 4 5 6 7 8 9 10 Next page

Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze